February 13, 2025 05:13 AM ESTUpdated 06:23 AM

Hunger-suppressing biotech Aardvark raises $94M in IPO

Kyle LaHucik

Senior Reporter

Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday with a $94 million debut on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hunger-suppressing biotech Aardvark raises $94M in IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

NIH’s funding cut plan poses challenges for researchers despite court halt

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Hunger-sup­press­ing biotech Aard­vark rais­es $94M in IPO

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Hunger-suppressing biotech Aardvark raises $94M in IPO